Loading…
Efficacy of 17α-hydroxyprogesterone caproate in prevention of preterm delivery
Aim: Preterm delivery is defined as a birth before 37 weeks' gestation and is the cause of two‐thirds of perinatal mortality and thus one of the major problems in obstetrics. Its etiology is unknown, but hormonal factors have been reported to play a part. Progesterone is a placental hormone an...
Saved in:
| Published in: | The journal of obstetrics and gynaecology research 2011-10, Vol.37 (10), p.1342-1345 |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4304-bd2304c4a95dc167b14acb61986701460e475c18663b195f4c24c5d67b8ea6683 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c4304-bd2304c4a95dc167b14acb61986701460e475c18663b195f4c24c5d67b8ea6683 |
| container_end_page | 1345 |
| container_issue | 10 |
| container_start_page | 1342 |
| container_title | The journal of obstetrics and gynaecology research |
| container_volume | 37 |
| creator | Saghafi, Nafiseh Khadem, Nayereh Mohajeri, Taraneh Shakeri, Mohamad Taghi |
| description | Aim: Preterm delivery is defined as a birth before 37 weeks' gestation and is the cause of two‐thirds of perinatal mortality and thus one of the major problems in obstetrics. Its etiology is unknown, but hormonal factors have been reported to play a part. Progesterone is a placental hormone and effective in maintaining pregnancy. The aim of this study is to evaluate the efficacy of 17α‐hydroxyprogesterone caproate in the prevention of preterm delivery.
Methods: This interventional study was performed with 100 pregnant women who had been referred to the Obstetrics Clinic of Ghaem Hospital (related to Mashhad University of Medical Sciences) during 2007 to 2008. They were randomly divided into two groups of 50 cases and 50 controls. The case group received 250 mg of intramuscular 17α‐hydroxyprogesterone caproate weekly from 16 weeks' gestation up to a maximum of 37 weeks' gestation. In the control group, routine perinatal care was performed and the pregnancy outcomes were compared in both groups.
Results: The mean gestational age was 36 weeks in the case group and 34 weeks in the control group. The mean birth weight was 2695 g in the case group and 2399 g in the control group. A significant difference was observed between the two groups in terms of gestational age and birth weight (P |
| doi_str_mv | 10.1111/j.1447-0756.2011.01524.x |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_900636829</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>900636829</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4304-bd2304c4a95dc167b14acb61986701460e475c18663b195f4c24c5d67b8ea6683</originalsourceid><addsrcrecordid>eNqNkEtOwzAQhi0EoqVwBZQdqwRP4keyYIGqEkBVuwGxtBzHgZQ8itOW5FhchDPhkNI13oxH_r_x6EPIAeyBPdcrDwjhLuaUeT4G8DBQn3jtERofHo7tPSDghpizETprmhXGwCMIT9HIB8oIwWyMlrMsy5VUnVNnDvDvL_etS03ddmtTv-pmo01daUdJ28qNdvLKWRu909Umr6sesZ3NlE6qi3ynTXeOTjJZNPpiXyfo-W72NL1358v4YXo7dxUJMHGT1LdFERnRVAHjCRCpEgZRyDgGwrAmnCoIGQsSiGhGlE8UTW0w1JKxMJigq2GuXexjaxcVZd4oXRSy0vW2ERHGLGChH9lkOCSVqZvG6EysTV5K0wnAorcpVqKXJnpporcpfm2K1qKX-0-2SanTA_inzwZuhsBnXuju34PF4zLub5Z3Bz63ptsDL827YDzgVLwsYgFzn0d0MRVx8ANMLZJG</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>900636829</pqid></control><display><type>article</type><title>Efficacy of 17α-hydroxyprogesterone caproate in prevention of preterm delivery</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Saghafi, Nafiseh ; Khadem, Nayereh ; Mohajeri, Taraneh ; Shakeri, Mohamad Taghi</creator><creatorcontrib>Saghafi, Nafiseh ; Khadem, Nayereh ; Mohajeri, Taraneh ; Shakeri, Mohamad Taghi</creatorcontrib><description>Aim: Preterm delivery is defined as a birth before 37 weeks' gestation and is the cause of two‐thirds of perinatal mortality and thus one of the major problems in obstetrics. Its etiology is unknown, but hormonal factors have been reported to play a part. Progesterone is a placental hormone and effective in maintaining pregnancy. The aim of this study is to evaluate the efficacy of 17α‐hydroxyprogesterone caproate in the prevention of preterm delivery.
Methods: This interventional study was performed with 100 pregnant women who had been referred to the Obstetrics Clinic of Ghaem Hospital (related to Mashhad University of Medical Sciences) during 2007 to 2008. They were randomly divided into two groups of 50 cases and 50 controls. The case group received 250 mg of intramuscular 17α‐hydroxyprogesterone caproate weekly from 16 weeks' gestation up to a maximum of 37 weeks' gestation. In the control group, routine perinatal care was performed and the pregnancy outcomes were compared in both groups.
Results: The mean gestational age was 36 weeks in the case group and 34 weeks in the control group. The mean birth weight was 2695 g in the case group and 2399 g in the control group. A significant difference was observed between the two groups in terms of gestational age and birth weight (P < 0.05).
Conclusion: Weekly administration of 17α‐hydroxyprogesterone caproate to pregnant women with a history of preterm delivery was associated with a decrease in preterm delivery and improvement in birth weight.</description><identifier>ISSN: 1341-8076</identifier><identifier>EISSN: 1447-0756</identifier><identifier>DOI: 10.1111/j.1447-0756.2011.01524.x</identifier><identifier>PMID: 21564406</identifier><language>eng</language><publisher>Melbourne, Australia: Blackwell Publishing Asia</publisher><subject>17α-hydroxyprogesterone caproate ; Adult ; birth weight ; Female ; gestational age ; Humans ; Hydroxyprogesterones - therapeutic use ; Obstetric Labor, Premature - drug therapy ; Obstetric Labor, Premature - prevention & control ; Pregnancy ; Pregnancy Outcome ; Premature Birth - drug therapy ; Premature Birth - prevention & control ; preterm birth ; Treatment Outcome</subject><ispartof>The journal of obstetrics and gynaecology research, 2011-10, Vol.37 (10), p.1342-1345</ispartof><rights>2011 The Authors. Journal of Obstetrics and Gynaecology Research © 2011 Japan Society of Obstetrics and Gynecology</rights><rights>2011 The Authors. Journal of Obstetrics and Gynaecology Research © 2011 Japan Society of Obstetrics and Gynecology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4304-bd2304c4a95dc167b14acb61986701460e475c18663b195f4c24c5d67b8ea6683</citedby><cites>FETCH-LOGICAL-c4304-bd2304c4a95dc167b14acb61986701460e475c18663b195f4c24c5d67b8ea6683</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21564406$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Saghafi, Nafiseh</creatorcontrib><creatorcontrib>Khadem, Nayereh</creatorcontrib><creatorcontrib>Mohajeri, Taraneh</creatorcontrib><creatorcontrib>Shakeri, Mohamad Taghi</creatorcontrib><title>Efficacy of 17α-hydroxyprogesterone caproate in prevention of preterm delivery</title><title>The journal of obstetrics and gynaecology research</title><addtitle>J Obstet Gynaecol Res</addtitle><description>Aim: Preterm delivery is defined as a birth before 37 weeks' gestation and is the cause of two‐thirds of perinatal mortality and thus one of the major problems in obstetrics. Its etiology is unknown, but hormonal factors have been reported to play a part. Progesterone is a placental hormone and effective in maintaining pregnancy. The aim of this study is to evaluate the efficacy of 17α‐hydroxyprogesterone caproate in the prevention of preterm delivery.
Methods: This interventional study was performed with 100 pregnant women who had been referred to the Obstetrics Clinic of Ghaem Hospital (related to Mashhad University of Medical Sciences) during 2007 to 2008. They were randomly divided into two groups of 50 cases and 50 controls. The case group received 250 mg of intramuscular 17α‐hydroxyprogesterone caproate weekly from 16 weeks' gestation up to a maximum of 37 weeks' gestation. In the control group, routine perinatal care was performed and the pregnancy outcomes were compared in both groups.
Results: The mean gestational age was 36 weeks in the case group and 34 weeks in the control group. The mean birth weight was 2695 g in the case group and 2399 g in the control group. A significant difference was observed between the two groups in terms of gestational age and birth weight (P < 0.05).
Conclusion: Weekly administration of 17α‐hydroxyprogesterone caproate to pregnant women with a history of preterm delivery was associated with a decrease in preterm delivery and improvement in birth weight.</description><subject>17α-hydroxyprogesterone caproate</subject><subject>Adult</subject><subject>birth weight</subject><subject>Female</subject><subject>gestational age</subject><subject>Humans</subject><subject>Hydroxyprogesterones - therapeutic use</subject><subject>Obstetric Labor, Premature - drug therapy</subject><subject>Obstetric Labor, Premature - prevention & control</subject><subject>Pregnancy</subject><subject>Pregnancy Outcome</subject><subject>Premature Birth - drug therapy</subject><subject>Premature Birth - prevention & control</subject><subject>preterm birth</subject><subject>Treatment Outcome</subject><issn>1341-8076</issn><issn>1447-0756</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNqNkEtOwzAQhi0EoqVwBZQdqwRP4keyYIGqEkBVuwGxtBzHgZQ8itOW5FhchDPhkNI13oxH_r_x6EPIAeyBPdcrDwjhLuaUeT4G8DBQn3jtERofHo7tPSDghpizETprmhXGwCMIT9HIB8oIwWyMlrMsy5VUnVNnDvDvL_etS03ddmtTv-pmo01daUdJ28qNdvLKWRu909Umr6sesZ3NlE6qi3ynTXeOTjJZNPpiXyfo-W72NL1358v4YXo7dxUJMHGT1LdFERnRVAHjCRCpEgZRyDgGwrAmnCoIGQsSiGhGlE8UTW0w1JKxMJigq2GuXexjaxcVZd4oXRSy0vW2ERHGLGChH9lkOCSVqZvG6EysTV5K0wnAorcpVqKXJnpporcpfm2K1qKX-0-2SanTA_inzwZuhsBnXuju34PF4zLub5Z3Bz63ptsDL827YDzgVLwsYgFzn0d0MRVx8ANMLZJG</recordid><startdate>201110</startdate><enddate>201110</enddate><creator>Saghafi, Nafiseh</creator><creator>Khadem, Nayereh</creator><creator>Mohajeri, Taraneh</creator><creator>Shakeri, Mohamad Taghi</creator><general>Blackwell Publishing Asia</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201110</creationdate><title>Efficacy of 17α-hydroxyprogesterone caproate in prevention of preterm delivery</title><author>Saghafi, Nafiseh ; Khadem, Nayereh ; Mohajeri, Taraneh ; Shakeri, Mohamad Taghi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4304-bd2304c4a95dc167b14acb61986701460e475c18663b195f4c24c5d67b8ea6683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>17α-hydroxyprogesterone caproate</topic><topic>Adult</topic><topic>birth weight</topic><topic>Female</topic><topic>gestational age</topic><topic>Humans</topic><topic>Hydroxyprogesterones - therapeutic use</topic><topic>Obstetric Labor, Premature - drug therapy</topic><topic>Obstetric Labor, Premature - prevention & control</topic><topic>Pregnancy</topic><topic>Pregnancy Outcome</topic><topic>Premature Birth - drug therapy</topic><topic>Premature Birth - prevention & control</topic><topic>preterm birth</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Saghafi, Nafiseh</creatorcontrib><creatorcontrib>Khadem, Nayereh</creatorcontrib><creatorcontrib>Mohajeri, Taraneh</creatorcontrib><creatorcontrib>Shakeri, Mohamad Taghi</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The journal of obstetrics and gynaecology research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Saghafi, Nafiseh</au><au>Khadem, Nayereh</au><au>Mohajeri, Taraneh</au><au>Shakeri, Mohamad Taghi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of 17α-hydroxyprogesterone caproate in prevention of preterm delivery</atitle><jtitle>The journal of obstetrics and gynaecology research</jtitle><addtitle>J Obstet Gynaecol Res</addtitle><date>2011-10</date><risdate>2011</risdate><volume>37</volume><issue>10</issue><spage>1342</spage><epage>1345</epage><pages>1342-1345</pages><issn>1341-8076</issn><eissn>1447-0756</eissn><abstract>Aim: Preterm delivery is defined as a birth before 37 weeks' gestation and is the cause of two‐thirds of perinatal mortality and thus one of the major problems in obstetrics. Its etiology is unknown, but hormonal factors have been reported to play a part. Progesterone is a placental hormone and effective in maintaining pregnancy. The aim of this study is to evaluate the efficacy of 17α‐hydroxyprogesterone caproate in the prevention of preterm delivery.
Methods: This interventional study was performed with 100 pregnant women who had been referred to the Obstetrics Clinic of Ghaem Hospital (related to Mashhad University of Medical Sciences) during 2007 to 2008. They were randomly divided into two groups of 50 cases and 50 controls. The case group received 250 mg of intramuscular 17α‐hydroxyprogesterone caproate weekly from 16 weeks' gestation up to a maximum of 37 weeks' gestation. In the control group, routine perinatal care was performed and the pregnancy outcomes were compared in both groups.
Results: The mean gestational age was 36 weeks in the case group and 34 weeks in the control group. The mean birth weight was 2695 g in the case group and 2399 g in the control group. A significant difference was observed between the two groups in terms of gestational age and birth weight (P < 0.05).
Conclusion: Weekly administration of 17α‐hydroxyprogesterone caproate to pregnant women with a history of preterm delivery was associated with a decrease in preterm delivery and improvement in birth weight.</abstract><cop>Melbourne, Australia</cop><pub>Blackwell Publishing Asia</pub><pmid>21564406</pmid><doi>10.1111/j.1447-0756.2011.01524.x</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1341-8076 |
| ispartof | The journal of obstetrics and gynaecology research, 2011-10, Vol.37 (10), p.1342-1345 |
| issn | 1341-8076 1447-0756 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_900636829 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | 17α-hydroxyprogesterone caproate Adult birth weight Female gestational age Humans Hydroxyprogesterones - therapeutic use Obstetric Labor, Premature - drug therapy Obstetric Labor, Premature - prevention & control Pregnancy Pregnancy Outcome Premature Birth - drug therapy Premature Birth - prevention & control preterm birth Treatment Outcome |
| title | Efficacy of 17α-hydroxyprogesterone caproate in prevention of preterm delivery |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T02%3A10%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%2017%CE%B1-hydroxyprogesterone%20caproate%20in%20prevention%20of%20preterm%20delivery&rft.jtitle=The%20journal%20of%20obstetrics%20and%20gynaecology%20research&rft.au=Saghafi,%20Nafiseh&rft.date=2011-10&rft.volume=37&rft.issue=10&rft.spage=1342&rft.epage=1345&rft.pages=1342-1345&rft.issn=1341-8076&rft.eissn=1447-0756&rft_id=info:doi/10.1111/j.1447-0756.2011.01524.x&rft_dat=%3Cproquest_cross%3E900636829%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4304-bd2304c4a95dc167b14acb61986701460e475c18663b195f4c24c5d67b8ea6683%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=900636829&rft_id=info:pmid/21564406&rfr_iscdi=true |